Roche News | finanzen.ch

Roche Aktie VALOR 1203211 / ISIN CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

23.08.23	[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer (GlobeNewswire)
27.07.23	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products (GlobeNewswire)
27.07.23	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten (GlobeNewswire)
24.07.23	Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk (GlobeNewswire)
21.07.23	CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA) (GlobeNewswire)
20.07.23	New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss (GlobeNewswire)
13.07.23	Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis (GlobeNewswire)
11.07.23	European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
30.06.23	Four-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk (GlobeNewswire)
16.06.23	FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
13.06.23	Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries (GlobeNewswire)
09.06.23	New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH) (GlobeNewswire)
17.05.23	Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis (GlobeNewswire)
09.05.23	FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) (GlobeNewswire)
04.05.23	Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems (GlobeNewswire)
26.04.23	CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
26.04.23	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 (GlobeNewswire)
26.04.23	[Ad-hoc-Mitteilung gemäss Art. 53 LR] Roche erzielt im ersten Quartal ein starkes Verkaufswachstum im Basisgeschäft beider Divisionen; Rückgang der Konzernverkäufe aufgrund der erwartungsgemäss gering (GlobeNewswire)
25.04.23	New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME (GlobeNewswire)
19.04.23	[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
16.04.23	Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study (GlobeNewswire)
13.04.23	Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 (GlobeNewswire)
22.03.23	Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease (GlobeNewswire)
20.03.23	New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA) (GlobeNewswire)
14.03.23	Roche Annual General Meeting 2023 (GlobeNewswire)
14.03.23	Roche Generalversammlung 2023 (GlobeNewswire)
10.03.23	FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
23.02.23	Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer (GlobeNewswire)
10.02.23	[Ad hoc-Mitteilung gemäss Art. 53 KR] Transaktion in Roche Inhaberaktien (GlobeNewswire)
10.02.23	[Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares (GlobeNewswire)
10.02.23	New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO) (GlobeNewswire)
14.11.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease (GlobeNewswire)
09.11.22	STRONG-HF study results demonstrate clear benefits for acute heart failure patients (GlobeNewswire)
03.11.22	Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs (GlobeNewswire)
27.10.22	Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO) (GlobeNewswire)
26.10.22	Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile (GlobeNewswire)
24.10.22	Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems (GlobeNewswire)
19.10.22	Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022 (GlobeNewswire)
18.10.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022 (GlobeNewswire)
18.10.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit soliden Ergebnissen in den ersten neun Monaten 2022 (GlobeNewswire)
12.10.22	Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use (GlobeNewswire)
12.10.22	Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA) (GlobeNewswire)
11.10.22	Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma (GlobeNewswire)
05.10.22	Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022 (GlobeNewswire)
04.10.22	Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU (GlobeNewswire)
03.10.22	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche: Wechsel in der Konzernleitung im Januar 2023 (GlobeNewswire)
03.10.22	[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023 (GlobeNewswire)
26.09.22	Change in the Roche Board of Directors (GlobeNewswire)
19.09.22	European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss (GlobeNewswire)
23.08.22	Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer